 | • レポートコード：MRC2Q12-19364 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、原発性免疫不全治療薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 原発性免疫不全治療薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 原発性免疫不全治療薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 原発性免疫不全治療薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの原発性免疫不全治療薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の原発性免疫不全治療薬の売上および2028年までの予測に焦点を当てています。 原発性免疫不全治療薬のグローバル主要企業には、ADMA Biologics, Inc.、CSL Behring, LLC、Octapharma、Takeda Pharmaceutical Company、Grifols Biologicals, Inc.、Baxter、Kedrion Biopharma、BPL Inc.、Pharming Group、Shire、Chengdu Rongsheng Pharmaceutical Co., Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 原発性免疫不全治療薬市場は、タイプとアプリケーションによって区分されます。世界の原発性免疫不全治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤 【アプリケーション別セグメント】 病院、専門クリニック、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 原発性免疫不全治療薬製品概要 - タイプ別市場（サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤） - アプリケーション別市場（病院、専門クリニック、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の原発性免疫不全治療薬販売量予測2017-2028 - 世界の原発性免疫不全治療薬売上予測2017-2028 - 原発性免疫不全治療薬の地域別販売量 - 原発性免疫不全治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別原発性免疫不全治療薬販売量 - 主要メーカー別原発性免疫不全治療薬売上 - 主要メーカー別原発性免疫不全治療薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤） - 原発性免疫不全治療薬のタイプ別販売量 - 原発性免疫不全治療薬のタイプ別売上 - 原発性免疫不全治療薬のタイプ別価格 ・アプリケーション別市場規模（病院、専門クリニック、その他） - 原発性免疫不全治療薬のアプリケーション別販売量 - 原発性免疫不全治療薬のアプリケーション別売上 - 原発性免疫不全治療薬のアプリケーション別価格 ・北米市場 - 北米の原発性免疫不全治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の原発性免疫不全治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの原発性免疫不全治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の原発性免疫不全治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の原発性免疫不全治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の原発性免疫不全治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の原発性免疫不全治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の原発性免疫不全治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの原発性免疫不全治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の原発性免疫不全治療薬市場規模（トルコ、サウジアラビア） ・企業情報 ADMA Biologics, Inc.、CSL Behring, LLC、Octapharma、Takeda Pharmaceutical Company、Grifols Biologicals, Inc.、Baxter、Kedrion Biopharma、BPL Inc.、Pharming Group、Shire、Chengdu Rongsheng Pharmaceutical Co., Ltd ・産業チェーン及び販売チャネル分析 - 原発性免疫不全治療薬の産業チェーン分析 - 原発性免疫不全治療薬の原材料 - 原発性免疫不全治療薬の生産プロセス - 原発性免疫不全治療薬の販売及びマーケティング - 原発性免疫不全治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 原発性免疫不全治療薬の産業動向 - 原発性免疫不全治療薬のマーケットドライバー - 原発性免疫不全治療薬の課題 - 原発性免疫不全治療薬の阻害要因 ・主な調査結果 |
Drugs for the treatment of primary immunodeficiency diseases
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Primary Immunodeficiency Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Primary Immunodeficiency Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Primary Immunodeficiency Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Primary Immunodeficiency Drugs include ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc. and Pharming Group, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Primary Immunodeficiency Drugs manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Primary Immunodeficiency Drugs market. Further, it explains the major drivers and regional dynamics of the global Primary Immunodeficiency Drugs market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
ADMA Biologics, Inc.
CSL Behring, LLC
Octapharma
Takeda Pharmaceutical Company
Grifols Biologicals, Inc.
Baxter
Kedrion Biopharma
BPL Inc.
Pharming Group
Shire
Chengdu Rongsheng Pharmaceutical Co., Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Primary Immunodeficiency Drugs Segment by Type
Cytokines
Anti Cytokine Antibodies
Signal Molecule Inhibitor
Primary Immunodeficiency Drugs Segment by Application
Hospital
Specialist Clinic
Othere
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Primary Immunodeficiency Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Primary Immunodeficiency Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Primary Immunodeficiency Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Primary Immunodeficiency Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Primary Immunodeficiency Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Primary Immunodeficiency Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Primary Immunodeficiency Drugs sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc. and Pharming Group, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Primary Immunodeficiency Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Primary Immunodeficiency Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Primary Immunodeficiency Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Primary Immunodeficiency Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Primary Immunodeficiency Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Cytokines
1.2.3 Anti Cytokine Antibodies
1.2.4 Signal Molecule Inhibitor
1.3 Market by Application
1.3.1 Global Primary Immunodeficiency Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Othere
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Primary Immunodeficiency Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Primary Immunodeficiency Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Primary Immunodeficiency Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Primary Immunodeficiency Drugs Sales by Region
2.4.1 Global Primary Immunodeficiency Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Primary Immunodeficiency Drugs by Region (2023-2028)
2.5 Global Primary Immunodeficiency Drugs Revenue by Region
2.5.1 Global Primary Immunodeficiency Drugs Revenue by Region (2017-2022)
2.5.2 Global Primary Immunodeficiency Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Primary Immunodeficiency Drugs Sales by Manufacturers
3.1.1 Global Top Primary Immunodeficiency Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Primary Immunodeficiency Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Primary Immunodeficiency Drugs in 2021
3.2 Global Primary Immunodeficiency Drugs Revenue by Manufacturers
3.2.1 Global Primary Immunodeficiency Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Primary Immunodeficiency Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Primary Immunodeficiency Drugs Revenue in 2021
3.3 Global Primary Immunodeficiency Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Primary Immunodeficiency Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Primary Immunodeficiency Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Primary Immunodeficiency Drugs Sales by Type
4.1.1 Global Primary Immunodeficiency Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Primary Immunodeficiency Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2028)
4.2 Global Primary Immunodeficiency Drugs Revenue by Type
4.2.1 Global Primary Immunodeficiency Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Primary Immunodeficiency Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Primary Immunodeficiency Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Primary Immunodeficiency Drugs Price by Type
4.3.1 Global Primary Immunodeficiency Drugs Price by Type (2017-2022)
4.3.2 Global Primary Immunodeficiency Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Primary Immunodeficiency Drugs Sales by Application
5.1.1 Global Primary Immunodeficiency Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Primary Immunodeficiency Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2028)
5.2 Global Primary Immunodeficiency Drugs Revenue by Application
5.2.1 Global Primary Immunodeficiency Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Primary Immunodeficiency Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Primary Immunodeficiency Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Primary Immunodeficiency Drugs Price by Application
5.3.1 Global Primary Immunodeficiency Drugs Price by Application (2017-2022)
5.3.2 Global Primary Immunodeficiency Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Primary Immunodeficiency Drugs Market Size by Type
6.1.1 North America Primary Immunodeficiency Drugs Sales by Type (2017-2028)
6.1.2 North America Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
6.2 North America Primary Immunodeficiency Drugs Market Size by Application
6.2.1 North America Primary Immunodeficiency Drugs Sales by Application (2017-2028)
6.2.2 North America Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
6.3 North America Primary Immunodeficiency Drugs Market Size by Country
6.3.1 North America Primary Immunodeficiency Drugs Sales by Country (2017-2028)
6.3.2 North America Primary Immunodeficiency Drugs Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Primary Immunodeficiency Drugs Market Size by Type
7.1.1 Europe Primary Immunodeficiency Drugs Sales by Type (2017-2028)
7.1.2 Europe Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
7.2 Europe Primary Immunodeficiency Drugs Market Size by Application
7.2.1 Europe Primary Immunodeficiency Drugs Sales by Application (2017-2028)
7.2.2 Europe Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
7.3 Europe Primary Immunodeficiency Drugs Market Size by Country
7.3.1 Europe Primary Immunodeficiency Drugs Sales by Country (2017-2028)
7.3.2 Europe Primary Immunodeficiency Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Primary Immunodeficiency Drugs Market Size by Type
8.1.1 Asia Pacific Primary Immunodeficiency Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Primary Immunodeficiency Drugs Market Size by Application
8.2.1 Asia Pacific Primary Immunodeficiency Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Primary Immunodeficiency Drugs Market Size by Region
8.3.1 Asia Pacific Primary Immunodeficiency Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Primary Immunodeficiency Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Primary Immunodeficiency Drugs Market Size by Type
9.1.1 Latin America Primary Immunodeficiency Drugs Sales by Type (2017-2028)
9.1.2 Latin America Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
9.2 Latin America Primary Immunodeficiency Drugs Market Size by Application
9.2.1 Latin America Primary Immunodeficiency Drugs Sales by Application (2017-2028)
9.2.2 Latin America Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
9.3 Latin America Primary Immunodeficiency Drugs Market Size by Country
9.3.1 Latin America Primary Immunodeficiency Drugs Sales by Country (2017-2028)
9.3.2 Latin America Primary Immunodeficiency Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Primary Immunodeficiency Drugs Market Size by Type
10.1.1 Middle East and Africa Primary Immunodeficiency Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Primary Immunodeficiency Drugs Market Size by Application
10.2.1 Middle East and Africa Primary Immunodeficiency Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Primary Immunodeficiency Drugs Market Size by Country
10.3.1 Middle East and Africa Primary Immunodeficiency Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Primary Immunodeficiency Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 ADMA Biologics, Inc.
11.1.1 ADMA Biologics, Inc. Corporation Information
11.1.2 ADMA Biologics, Inc. Overview
11.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 ADMA Biologics, Inc. Recent Developments
11.2 CSL Behring, LLC
11.2.1 CSL Behring, LLC Corporation Information
11.2.2 CSL Behring, LLC Overview
11.2.3 CSL Behring, LLC Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 CSL Behring, LLC Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 CSL Behring, LLC Recent Developments
11.3 Octapharma
11.3.1 Octapharma Corporation Information
11.3.2 Octapharma Overview
11.3.3 Octapharma Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Octapharma Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Octapharma Recent Developments
11.4 Takeda Pharmaceutical Company
11.4.1 Takeda Pharmaceutical Company Corporation Information
11.4.2 Takeda Pharmaceutical Company Overview
11.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Takeda Pharmaceutical Company Recent Developments
11.5 Grifols Biologicals, Inc.
11.5.1 Grifols Biologicals, Inc. Corporation Information
11.5.2 Grifols Biologicals, Inc. Overview
11.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Grifols Biologicals, Inc. Recent Developments
11.6 Baxter
11.6.1 Baxter Corporation Information
11.6.2 Baxter Overview
11.6.3 Baxter Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Baxter Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Baxter Recent Developments
11.7 Kedrion Biopharma
11.7.1 Kedrion Biopharma Corporation Information
11.7.2 Kedrion Biopharma Overview
11.7.3 Kedrion Biopharma Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Kedrion Biopharma Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Kedrion Biopharma Recent Developments
11.8 BPL Inc.
11.8.1 BPL Inc. Corporation Information
11.8.2 BPL Inc. Overview
11.8.3 BPL Inc. Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 BPL Inc. Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 BPL Inc. Recent Developments
11.9 Pharming Group
11.9.1 Pharming Group Corporation Information
11.9.2 Pharming Group Overview
11.9.3 Pharming Group Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Pharming Group Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Pharming Group Recent Developments
11.10 Shire
11.10.1 Shire Corporation Information
11.10.2 Shire Overview
11.10.3 Shire Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Shire Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shire Recent Developments
11.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
11.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
11.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Overview
11.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Primary Immunodeficiency Drugs Industry Chain Analysis
12.2 Primary Immunodeficiency Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Primary Immunodeficiency Drugs Production Mode & Process
12.4 Primary Immunodeficiency Drugs Sales and Marketing
12.4.1 Primary Immunodeficiency Drugs Sales Channels
12.4.2 Primary Immunodeficiency Drugs Distributors
12.5 Primary Immunodeficiency Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Primary Immunodeficiency Drugs Industry Trends
13.2 Primary Immunodeficiency Drugs Market Drivers
13.3 Primary Immunodeficiency Drugs Market Challenges
13.4 Primary Immunodeficiency Drugs Market Restraints
14 Key Findings in The Global Primary Immunodeficiency Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer